Navigation Links
Medarex in Medical News

PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)

ANNAPOLIS, Md. and PRINCETON, N.J., Nov. 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, and Medarex, Inc. (Nasdaq: MEDX ), a leading monoclonal antibody company, today announced that...

Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody

Addition of Hepatitis C Treatment to Ongoing Oncology Program for MDX-1106 PRINCETON, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Ono Pharmaceutical Co., Ltd. and Medarex, Inc. (Nasdaq: MEDX ) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food &...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...rma Services Becomes Recommended CRO for Multiple Myeloma Drug R&D II-53 Celgene Certifies McKesson Specialty to Launch Revlimid II-53 medarex and PacMab to Co-Develop Blood Cancer Therapies II-53 Gamida Cell and Teva to Co-Develop Therapy for Hematological Malignancies II-54 Glax...

Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research

...fully human, non-fucosylated antibody. About medarex medarex is a biopharmaceutical company focused on the disc...ion, autoimmune disorders and infectious diseases. medarex applies its UltiMAb(R) technology and product deve...

Medarex to Receive Milestone Payment for Approval of SIMPONI(TM) for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

.... Under the agreement with Centocor Ortho Biotech, medarex will receive future sales-based royalty payments f...opment for the treatment of cancer. About medarex medarex is a biopharmaceutical company focused on the disc...

Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City

...l, Senior Vice President of Product Development at medarex presented highlights from key programs in Medarex'...available in the Investor Relations section of the medarex website at www.medarex.com . Highlights from...In addition to the highlighted oncology portfolio, medarex is developing a number of promising products outsi...

Medarex Announces 2008 Fourth Quarter and Year End Financial Results

...oximately $1.7 million related to Celldex . medarex ended 2008 with approximately $353.7 million in ca...or the three-month period ended December 31, 2008, medarex reported a net loss of $43.0 million, or ($0.33) p..., or approximately $146 million for the full year. medarex currently expects its cash burn rate for the full ...

Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009

...ational); passcode number 263-79-360. About medarex medarex is a biopharmaceutical company focused on the disc...ion, autoimmune disorders and infectious diseases. medarex applies its UltiMAb(R) technology and product deve...

Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546

...er 2004, MedImmune entered into collaboration with medarex to focus on two specific antibodies, MDX-1103 (now...vities. Prior to the beginning of pivotal studies, medarex may elect to co-develop the products in return for... profits in the United States. In all other cases, medarex will be entitled to receive milestone payments and...

Medarex Reviews Recent Highlights and Outlook for 2009

...Howard H. Pien. Financial Guidance Update medarex is committed to the consistent management of resou...cross the organization. For the full year of 2008, medarex currently expects a cash burn rate per month of ap...d the net contributions to the ipilimumab program. medarex expects its monthly cash burn rate per month for t...
Medarex in Medical Technology

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338

...ted States will be diagnosed with AML. About medarex medarex is a biopharmaceutical company focused on the disc...ion, autoimmune disorders and infectious diseases. medarex applies its UltiMAb(R) technology, product develop...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

...000 Americans with ulcerative colitis. About medarex medarex is a biopharmaceutical company focused on the disc...ion, autoimmune disorders and infectious diseases. medarex applies its UltiMAb(R) technology and product deve...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

...eeting may be found at www.aacr.org . About medarex medarex is a biopharmaceutical company focused on the disc...ion, autoimmune disorders and infectious diseases. medarex applies its UltiMAb(R) technology and product deve...

Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma

...nd initial efficacy of the antibody. About medarex medarex is a biopharmaceutical company focused on the disc...gulatory applications for marketing authorization. medarex is committed to building value by developing a div...

Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer

...5, Ono entered into a collaboration agreement with medarex to research and develop a fully human anti-PD-1 an...cluding with anti-CTLA-4 blockade. About medarex medarex is a biopharmaceutical company focused on the disc...

Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors

...s generated using Medarex's UltiMAb(R) technology. medarex may receive future milestone payments and royaltie...n, President and CEO of Medarex. About Medarex medarex is a biopharmaceutical company focused on the disc...gulatory applications for marketing authorization. medarex is committed to building value by developing a div...

Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing

...body generated by Medarex's UltiMAb(R) technology. medarex may receive future milestone payments and royaltie...reat life-threatening diseases." About Medarex medarex is a biopharmaceutical company focused on the disc...gulatory applications for marketing authorization. medarex is committed to building value by developing a div...

Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology

...e found at http://www.esmo.org . About Medarex medarex is a biopharmaceutical company focused on the disc...gulatory applications for marketing authorization. medarex is committed to building value by developing a div...ite at http://www.medarex.com . Medarex(R), the medarex logo and UltiMAb(R) are registered trademarks of M...

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus

... medarex to Receive Milestone Payment from MedImmune PRIN...vities. Prior to the beginning of pivotal studies, medarex may elect to co-develop the products in return for... profits in the United States. In all other cases, medarex will be entitled to receive milestone payments and...

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105

... cancer and infectious disease." About Medarex medarex is a biopharmaceutical company focused on the disc...gulatory applications for marketing authorization. medarex is committed to building value by developing a div..., visit its website at http://www.medarex.com . medarex Statement on Cautionary Factors Except for the h...
Medarex in Biological News

Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck

WHITEHOUSE STATION N.J., PRINCETON, N.J. and JAMAICA PLAIN, Mass., April 21, 2009 Merck & Co., Inc., (through an affiliate), Medarex, Inc. (NASDAQ: MEDX) and Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that they have signed an...
Medarex in Biological Technology

BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology

PRINCETON, N.J., July 16 /PRNewswire-FirstCall/ -- BioWa, Inc. and Medarex, Inc. (Nasdaq: MEDX ) announced today that they have entered into a license agreement which provides Medarex with the first ever access to BioWa's COMPLEGENT(TM) Technology for enhancing the complement-dependent cytoto...

Biotech Hot in July Driven by Positive Drug Data and Acquisitions

...e sponsorship and three other antibodies being co-developed with other partners, and rights to pre-clinical assets in various stages of development by medarex - in particular, monoclonal antibodies focused in oncology and immunology. It wasn't all good news for biotechs. Genzyme shares tumbled more th...

Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009

...., Senior Vice President of Product Development at medarex will provide an update and recent highlights from ...nal); the replay passcode is 4826956. About medarex medarex is a biopharmaceutical company focused on the disc...

Medarex Announces 2009 First Quarter Financial Results

...2.4 million in 2008 to $10.5 million in 2009. medarex ended the first quarter of 2009 with approximately... During the first quarter, medarex received a milestone payment from its partner, Med...proval. In connection with the approval in Canada, medarex received an undisclosed milestone payment from lic...

Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009

...ternational); passcode number 1477334. About medarex medarex is a biopharmaceutical company focused on the dis...ion, autoimmune disorders and infectious diseases. medarex applies its UltiMAb(R) technology and product deve...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

...eeting may be found at www.asco.org . About medarex medarex is a biopharmaceutical company focused on the disc...ion, autoimmune disorders and infectious diseases. medarex applies its UltiMAb(R) technology and product deve...

Medarex to Present at the Needham Cancer Therapeutics Conference

...available in the Investor Relations section of the medarex website at www.medarex.com . An archived edition ...will be available following the event. About medarex medarex is a biopharmaceutical company focused on the disc...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

...eeting may be found at www.aacr.org . About medarex medarex is a biopharmaceutical company focused on the disc...ion, autoimmune disorders and infectious diseases. medarex applies its UltiMAb(R) technology and product deve...

Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203

...arex's Antibody-Drug Conjugate (ADC) Technology medarex has enhanced its core UltiMAb(R) antibody platform...o an antibody using a stable peptide-based linker. medarex believes that its ADC technology overcomes many of...ide therapeutic window with minimal toxicity. medarex has conducted multiple preclinical studies on seve...

Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference

...available in the Investor Relations section of the medarex website at www.medarex.com . An archived edition ...will be available following the event. About medarex medarex is a biopharmaceutical company focused on the disc...
Other Tags
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe ... the very first small business donation to kick off the campaign for healing and ... Her legacy includes a complete line of raw, organic hair care products, as well ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by ... predictive health analytics , Jvion continues to disrupt the predictive analytic and ... that targets patient and population level illness to drive prevention and better health ...
(Date:7/31/2015)... Jacksonville, FL (PRWEB) , ... July 31, 2015 ... ... has announced an important workshop at its new True North Conference Center. The ... attend so that the Jacksonville community may be more aligned in the effort ...
(Date:7/31/2015)... , ... July 31, 2015 , ... According to the article published July ... the Pasadena courthouse was contained and extinguished by the city’s fire department before it caused ... building at the time of the fire, and it was a fire alarm system that ...
Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
Other Contents